Detalhe da pesquisa
1.
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
Am J Respir Crit Care Med
; 198(10): 1268-1278, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29763572
2.
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting ß2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Am J Respir Crit Care Med
; 194(5): 559-67, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27585384
3.
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
Eur Respir J
; 43(6): 1599-609, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24176997
4.
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
Eur Respir J
; 40(5): 1106-14, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23060624
5.
Transforming growth factor-beta 1 induces angiogenesis in vitro via VEGF production in human airway smooth muscle cells.
Indian J Biochem Biophys
; 48(4): 262-9, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22053695
6.
Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
Lancet Respir Med
; 9(2): 149-158, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010810
7.
Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma.
J Allergy Clin Immunol Pract
; 9(8): 3069-3077.e6, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33895362
8.
Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies.
Drug Saf
; 44(4): 467-478, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33548020
9.
Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Lancet Respir Med
; 6(11): 827-836, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30224319
10.
Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy.
Cell Biochem Biophys
; 47(1): 131-48, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17406066
11.
Vasoactive peptides upregulate mRNA expression and secretion of vascular endothelial growth factor in human airway smooth muscle cells.
Cell Biochem Biophys
; 47(1): 109-18, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17406064
12.
Role of extracellular matrix and its regulators in human airway smooth muscle biology.
Cell Biochem Biophys
; 44(1): 139-46, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16456242
13.
Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease.
Am J Clin Pathol
; 126(5): 725-35, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17111536
14.
Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function".
J Allergy Clin Immunol Pract
; 9(11): 4179-4180, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34749952
15.
Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart.
Vascul Pharmacol
; 42(5-6): 281-9, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15905131
16.
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Int J Chron Obstruct Pulmon Dis
; 8: 501-8, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24159259
17.
Nitric oxide donors augment interleukin-1ß-induced vascular endothelial growth factor in airway smooth muscle cells.
Cell Biochem Biophys
; 67(2): 247-54, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24142467
18.
Angiogenesis and vascular remodeling in chronic airway diseases.
Cell Biochem Biophys
; 67(2): 219-34, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23975597
19.
Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Respir Med
; 107(10): 1558-67, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23867808
20.
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Lancet Respir Med
; 1(1): 51-60, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24321804